Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TML-6 in Early Alzheimer’s Disease
2026-525539-18-00Phase 2Authorised
- Sponsor
- Merry Life Biomedical Co., Ltd.
- Start
- Aug 2026
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing TML-6 with TML-6 matching placebo (2 arms). Primary endpoint: Change in CDR-SB from baseline to Week 52. Planned start Aug 2026; status: authorised.
02
Drugs
TML-6
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2026-525539-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525539-18-00.